logo-loader
viewMidatech Pharma PLC

Midatech Pharma starts phase 1 trial of hormonal cancer treatment

Following dosing, all subjects will enter a 63-day observation and sampling period.  

Midatech Pharma PLC -

Midatech Pharma PLC (LON:MTPH) has started to dose patients in its phase 1 study of MTD201, a possible new treatment for hormonal-based cancers such as acromegaly and neuroendocrine tumours (NET).  

The first cohort of healthy volunteers, 14 out of 28 subjects, received one dose of Sandostatin 100 microgram/1 ml solution on 5 October, which has been followed by a 30mg injection of MTD201.

The remaining 14 subjects will undergo the same procedures this week to complete the dosing phase of the study.

Following dosing, all subjects will enter a 63-day observation and sampling period.  

Topline results expected by the end of 2019 or early in 2020.

Midatech is developing therapies using three novel delivery mechanisms.

MTD201 uses Q-Sphera, a polymer microsphere innovation used to prolong and control the release of therapeutics over an extended period of time -from weeks to months.

Quick facts: Midatech Pharma PLC

Price: 2.6 GBX

AIM:MTPH
Market: AIM
Market Cap: £12.22 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Midatech Pharma PLC named herein, including the promotion by the Company of Midatech Pharma PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: accesso Technology announces deal with The New York...

Top stories from the Proactive Investors UK newsroom: accesso Technology Group PLC (LON:ACSO) has signed a three-year partnership with The New York Botanical Garden (NYBG) to supply its Passport, Siriusware and Ingresso products. Based near The Bronx, the NYBG attracts over 1mln visitors...

on 13/6/19

2 min read